Month: October 2020

Icon Genetics clinical development of its novel norovirus vaccine reaches milestone of complete dosing of the first cohort

Posted by

Halle (Saale), Octo­ber 2, 2020. Icon Genet­ics GmbH, a whol­ly owned sub­sidiary of Den­ka Co. Ltd, Tokyo, Japan, has ini­ti­at­ed a Phase I clin­i­cal study of its norovirus vac­cine can­di­date in August, 2020 and now suc­cess­ful­ly final­ized dos­ing of the first of two cohorts. The tri­al is a sin­­gle-cen­ter, ran­dom­ized, dou­ble-blind, con­trolled study that has… Read more »